<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104257">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01968161</url>
  </required_header>
  <id_info>
    <org_study_id>IIS - Switch Asenapine</org_study_id>
    <nct_id>NCT01968161</nct_id>
  </id_info>
  <brief_title>Investigator Initiated Study - Asenapine Early Psychosis</brief_title>
  <official_title>An Open-label Switch Study to Asenapine in the Early Stage of Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose a use of a unique facility, the databank at the CNDV, to examine the impact of
      switching subjects to asenapine in an open-label naturalistic setting. This offers the
      following advantages: i) providing data on a particularly important population, i.e.,
      subjects who are at the inception of treatment for a psychotic disorder and who are likely
      to remain on a given drug on a long-term basis; ii) its inclusion in a rich clinical
      setting, with a clinical team dedicated to provide innovative interventions; iii) its
      naturalistic design, that will allow to obtain data that will be applicable to &quot;real-life&quot;
      clinical settings; indeed, subjects who will be switched to asenapine within the current
      project are those we would switch to this drug in our daily practice.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Impact of switching to asenapine</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictors of successful switch to asenapine</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Schizophrenia and Disorders With Psychotic Features</condition>
  <condition>Disorders</condition>
  <arm_group>
    <arm_group_label>Asenapine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open label switch to asenapine: asenapine will be introduced at the target dose (5 mg bid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine</intervention_name>
    <arm_group_label>Asenapine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meeting DSM-IV criteria for schizophrenia (SZ) or related SZ spectrum psychotic
             disorders

          -  having provided a consent to include data on our databank,and being able to provide
             informed consent

          -  willingness to participate to the assessments

          -  being over 18 years of age

          -  being in a clinical situation that warrants switch to asenapine

        Exclusion Criteria:

          -  suffering from a primary drug-induced psychosis

          -  being at significant risk for suicide or assault

          -  unstable medical condition

          -  persistence of psychotic symptoms despite adequate treatment to an extent that
             clozapine would be required

          -  being treated with antipsychotic for 5 years or more

          -  having contraindications(allergy to asenapine)

          -  being pregnant or lactating
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc-André Roy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Notre-Dame des Victoires</name>
      <address>
        <city>Quebec</city>
        <zip>G1K 4B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Pasat, BSc</last_name>
      <phone>418-694-2223</phone>
      <email>diana.pasat@yahoo.ca</email>
    </contact>
    <investigator>
      <last_name>Marc-Andre Roy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 8, 2014</lastchanged_date>
  <firstreceived_date>October 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Schizophrenia and Disorders with Psychotic Features</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asenapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
